Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
CTDNA testing might provide an assessment of the genomic profile of advanced cancer without the need to repeat tumor biopsy. We did an open-label, multicohort, phase 2a, platform trial of ctDNA testing in 18 UK hospitals. Patients were recruited into four parallel treatment cohorts matched to mutations identified in ct DNA.
